Literature DB >> 26464382

Glucose fluctuation increased hepatocyte apoptosis under lipotoxicity and the involvement of mitochondrial permeability transition opening.

Xueyao Yin1, Fenping Zheng1, Qianqian Pan1, Saifei Zhang1, Dan Yu1, Zhiye Xu1, Hong Li2.   

Abstract

Oxidative stress is considered to be an important factor in producing lethal hepatocyte injury associated with nonalcoholic fatty liver disease (NAFLD). Glucose fluctuation, more pronounced in patients with diabetes, has been recognized as an even stronger oxidative stress inducer than the sustained hyperglycemia. Here, we investigated the role of glucose variability in the development of the NAFLD based on hepatocyte apoptosis and possible mechanisms. To achieve this goal we studied C57BL/6J mice that were maintained on a high fat diet (HFD) and injected with glucose (3 g/kg) twice daily to induce intermittent high glucose (IHG). We also studied hepatic L02 cells incubated with palmitic acid (PA) to induce steatosis. The following experimental groups were compared: normal glucose (NG), sustained high glucose (SHG) and IHG with or without PA. We found that, although hepatic enzyme levels and liver lipid deposition were comparable between HFD mice injected with glucose or saline, the glucose injected mice displayed marked hepatocyte apoptosis and inflammation, accompanied by increased lipid peroxide in liver. In vitro, in the presence of PA, IHG increased L02 cell apoptosis and oxidative stress and produced pronounced mitochondrial dysfunction relative to the NG and SHG groups. Furthermore, treatment with the mitochondrial permeability transition (MPT) inhibitor, cyclosporin A (1.5 μmol/l), prevented mitochondrial dysfunction, oxidative stress and hepatocyte apoptosis. Our data suggests that IHG under lipotoxicity might contribute to the development of NAFLD by increasing oxidative stress and hepatocyte apoptosis via MPT and its related mitochondrial dysfunction.
© 2015 Society for Endocrinology.

Entities:  

Keywords:  apoptosis; glucose fluctuation; mitochondrial permeability transition; nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2015        PMID: 26464382     DOI: 10.1530/JME-15-0101

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  24 in total

1.  Uncoupling Protein 2 Inhibition Exacerbates Glucose Fluctuation-Mediated Neuronal Effects.

Authors:  Susana Cardoso; Raquel M Seiça; Paula I Moreira
Journal:  Neurotox Res       Date:  2017-09-05       Impact factor: 3.911

2.  Intermittent high glucose induces pyroptosis of rat H9C2 cardiomyocytes via sodium-glucose cotransporter 1.

Authors:  Qian Chai; Ziang Meng; Dexue Lu; Ziying Zhang; Meili Liu; Weihua Wu
Journal:  Mol Cell Biochem       Date:  2021-02-19       Impact factor: 3.396

3.  Diet-dependent retinoid effects on liver gene expression include stellate and inflammation markers and parallel effects of the nuclear repressor Shp.

Authors:  Meghan Maguire; Justin R Bushkofsky; Michele Campaigne Larsen; Yee Hoon Foong; Sherry A Tanumihardjo; Colin R Jefcoate
Journal:  J Nutr Biochem       Date:  2017-04-19       Impact factor: 6.048

4.  Exercise-Induced Autophagy in Fatty Liver Disease.

Authors:  Sung Kook Chun; Sooyeon Lee; Ming-Jim Yang; Christiaan Leeuwenburgh; Jae-Sung Kim
Journal:  Exerc Sport Sci Rev       Date:  2017-07       Impact factor: 6.230

5.  Glycemic variability predicts inflammation in adolescents with type 1 diabetes.

Authors:  Robert P Hoffman; Amanda S Dye; Hong Huang; John A Bauer
Journal:  J Pediatr Endocrinol Metab       Date:  2016-10-01       Impact factor: 1.634

6.  Cyp1b1 affects external control of mouse hepatocytes, fatty acid homeostasis and signaling involving HNF4α and PPARα.

Authors:  Justin R Bushkofsky; Meghan Maguire; Michele Campaigne Larsen; Yee Hoon Fong; Colin R Jefcoate
Journal:  Arch Biochem Biophys       Date:  2016-03-29       Impact factor: 4.013

Review 7.  Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy.

Authors:  Jianan Zhao; Yiyang Hu; Jinghua Peng
Journal:  Cell Mol Biol Lett       Date:  2021-05-07       Impact factor: 5.787

Review 8.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 9.  Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021

Review 10.  Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease.

Authors:  Jianan Zhao; Yu Zhao; Yiyang Hu; Jinghua Peng
Journal:  Cell Mol Biol Lett       Date:  2021-07-07       Impact factor: 5.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.